Condition: DLBCL - Diffuse Large B Cell Lymphoma · Markers of Inflammation · Sponsor: Ain Shams University
This observational study evaluates the predictive value of systemic inflammatory markers-CRP, albumin, CRP-to-albumin ratio (CAR), and modified Glasgow Prognostic Score (mGPS)-in patients with diffuse large B-cell lymphoma (DLBCL) receiving R-CHOP chemotherapy. The study examines associations with treatment response, toxicity, and clinical characteristics.
This description comes directly from the study's public registry record.
Alaa M Elsayed, MSc · +201112490913 · alaa.abdou@med.asu.edu.eg
Always discuss trial participation with your own doctor first.
| Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Ain Shams University | Cairo, Cairo Governorate, Egypt | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07057765